{"id":"NCT02442765","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","briefTitle":"Efficacy, Safety and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type","officialTitle":"A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 (Deuterated [d6]-Dextromethorphan Hydrobromide [d6-DM]/Quinidine Sulfate [Q]) for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-07-23","primaryCompletion":"2019-01-30","completion":"2019-02-27","firstPosted":"2015-05-13","resultsPosted":"2023-02-13","lastUpdate":"2023-02-13"},"enrollment":387,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Agitation in Patients With Dementia of the Alzheimer's Type"],"interventions":[{"type":"DRUG","name":"AVP-786","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Stage 1: Placebo","type":"PLACEBO_COMPARATOR"},{"label":"Stage 1: AVP-786-18 (d6-DM 18 mg/Q 4.9 mg)","type":"EXPERIMENTAL"},{"label":"Stage 1: AVP-786-28 (d6-DM 28 mg/Q 4.9 mg)","type":"EXPERIMENTAL"},{"label":"Stage 2: Placebo","type":"PLACEBO_COMPARATOR"},{"label":"Stage 1: AVP-786-18 (d6-DM 18 mg/Q 4.9 mg) to: Stage 2: AVP-786-18 (d6-DM 18 mg/Q 4.9 mg)","type":"EXPERIMENTAL"},{"label":"Stage 1: AVP-786-28 (d6-DM 28 mg/Q 4.9 mg) to Stage 2: AVP-786-28 (d6-DM 28 mg/Q 4.9 mg)","type":"EXPERIMENTAL"},{"label":"Experimental: Stage 1: Placebo to: Stage 2: AVP-786-18 d6-DM 18 mg/Q 4.9 mg","type":"EXPERIMENTAL"},{"label":"Stage 1: Placebo to: Stage 2: AVP-786-28 d6 DM 28 mg/Q 4.9 mg","type":"EXPERIMENTAL"}],"summary":"Participants with agitation secondary to dementia of the Alzheimer's type. The diagnosis of probable Alzheimer's disease (AD) was to be based on the \"2011 Diagnostic Guidelines for Alzheimer's Disease\" issued by the National Institute on Aging (NIA)-Alzheimer's Association (AA) workgroups.","primaryOutcome":{"measure":"Stage 1 and Stage 2: Change From Baseline in the Cohen-Mansfield Agitation Inventory (CMAI) Composite Score to Week 6 and Week 12","timeFrame":"Stage 1: Baseline, Week 6; Stage 2: Baseline (Week 6), Week 12","effectByArm":[{"arm":"Stage 1: Placebo","deltaMin":73.9,"sd":22.23},{"arm":"Stage 1: AVP-786-18 (d6-DM 18 mg/Q 4.9 mg)","deltaMin":72.3,"sd":23.08},{"arm":"Stage 1: AVP-786-28 (d6-DM 28 mg/Q 4.9 mg)","deltaMin":71.7,"sd":23.57}],"pValues":[{"comp":"OG000 vs OG001","p":"=0.021"},{"comp":"OG000 vs OG002","p":"=0.731"},{"comp":"OG003 vs OG004","p":"=0.157"},{"comp":"OG003 vs OG005","p":"=0.150"},{"comp":"OG000 vs OG001 vs OG003 vs OG004","p":"=0.008"},{"comp":"OG000 vs OG002 vs OG003 vs OG005","p":"=0.208"}]},"eligibility":{"minAge":"50 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":7,"exclusionCount":3},"locations":{"siteCount":126,"countries":["United States","Estonia","Germany","Poland","Portugal","Puerto Rico"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":6,"n":194},"commonTop":["Fall","Urinary tract infection","Diarrhoea","Agitation","Somnolence"]}}